ArticleACG case reports journal2022
Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis.
Article in ACG case reports journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Review
- Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research.Journal of clinical medicine · 2024Review
- Unresolved challenges in acute severe ulcerative colitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.Journal of Crohn's & colitis · 2023Review
- Case Report: Medical Management of Acute Severe Ulcerative Colitis.Gastroenterology & hepatology · 2023Article
- Salvage Therapy in Acute Severe Ulcerative Colitis: Current Practice and a Look to the Future.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ozanimod has recently received US Food and Drug Administration approval for moderate-to-severe ulcerative colitis. Treatment of acute severe colitis remains a clinical challenge, and although many patients respond to cyclosporine therapy, there remains a relative paucity of maintenance options. This case report describes the first reported, successful use of ozanimod after hospitalization for acute severe ulcerative colitis and in tandem with cyclosporine. Although a longer follow-up is required, this report shows the feasibility of ozanimod in this clinical setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.